ProKidney Corp
PROK2.890USD
+0.080+2.85%
Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min
385.58MCap. mercado
PérdidaP/E TTM
Más Datos de ProKidney Corp Compañía
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Información de ProKidney Corp
Símbolo de cotizaciónPROK
Nombre de la empresaProKidney Corp
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoDr. Bruce Culleton, M.D.
Número de empleados204
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 30
Dirección2000 Frontis Plaza Blvd.
CiudadWINSTON-SALEM
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal27103
Teléfono13369997028
Sitio Webhttps://prokidney.com/
Símbolo de cotizaciónPROK
Fecha de salida a bolsaJun 30, 2021
Director ejecutivoDr. Bruce Culleton, M.D.
Ejecutivos de ProKidney Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. Ethan Holdaway
Mr. Ethan Holdaway
Investor Relations
Investor Relations
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
--
Mr. Ethan Holdaway
Mr. Ethan Holdaway
Investor Relations
Investor Relations
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 8 de nov
Actualizado: sáb., 8 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
Otro
59.39%
Accionistas
Accionistas
Proporción
Tolerantia LLC
16.75%
Suvretta Capital Management, LLC
9.14%
Control Empresarial de Capitales, S.A. de C.V.
7.94%
Morgan Stanley Investment Management Inc. (US)
4.23%
BlackRock Mexico Operadora SA de CV SOFI
2.54%
Otro
59.39%
Tipos de accionistas
Accionistas
Proporción
Corporation
24.70%
Hedge Fund
10.27%
Investment Advisor
10.23%
Investment Advisor/Hedge Fund
5.98%
Research Firm
2.84%
Individual Investor
1.92%
Endowment Fund
0.74%
Family Office
0.04%
Bank and Trust
0.04%
Otro
43.25%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
180
38.60M
28.59%
-15.99M
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
2023Q2
223
59.02M
95.83%
-21.49M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tolerantia LLC
22.62M
16.75%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
9.14%
--
--
Jun 30, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
7.94%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
5.71M
4.23%
-4.33M
-43.14%
Jun 30, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.54%
--
--
Aug 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.81%
--
--
Aug 31, 2025
Bleichroeder LP
2.00M
1.48%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
1.27%
-4.60M
-72.83%
Jun 30, 2025
The Vanguard Group, Inc.
1.57M
1.16%
-3.64M
-69.92%
Jun 30, 2025
Culleton (Bruce)
1.54M
1.14%
+1.54M
--
Mar 17, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Schwab U.S. Small-Cap ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Ver más
Schwab U.S. Small-Cap ETF
Proporción0.01%
ALPS Medical Breakthroughs ETF
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Schwab U.S. Broad Market ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Avantis US Equity ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
